Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis (Q37879190)

24 August 2017

1 reference

title

Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis (English)

1 reference

24 August 2017

0 references

0 references

Mark Tidswell

1

1 reference

24 August 2017

Steven P LaRosa

series ordinal

2

1 reference

24 August 2017

publication date

1 May 2011

1 reference

Expert Review of Anti-infective Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

9

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

507-520

1 reference

Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock

24 August 2017

cites work

1 reference

Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study

21 January 2018

1 reference

Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Molecular biology of inflammation and sepsis: a primer

21 January 2018

1 reference

Pathogen recognition and innate immunity

21 January 2018

1 reference

MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4

21 January 2018

1 reference

Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa.

21 January 2018

1 reference

Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran

21 January 2018

1 reference

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

21 January 2018

1 reference

Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin

21 January 2018

1 reference

Innate immune sensing and its roots: the story of endotoxin

21 January 2018

1 reference

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

Toll-like receptor signalling

21 January 2018

1 reference

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

21 January 2018

1 reference

Bench-to-bedside review: Cytopathic hypoxia

21 January 2018

1 reference

Hmgb-1 as a therapeutic target for infectious and inflammatory disorders.

21 January 2018

1 reference

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

21 January 2018

1 reference

The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome

21 January 2018

1 reference

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis

21 January 2018

1 reference

Therapeutic approaches to superantigen‐based diseases: a review

21 January 2018

1 reference

Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis.

21 January 2018

1 reference

Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection

21 January 2018

1 reference

21 January 2018

1 reference

Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis

21 January 2018

1 reference

Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.

21 January 2018

1 reference

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

21 January 2018

1 reference

The Primary Role of Lymphoreticnlar Cells in the Mediation of Host Responses to Bacterial Endotoxim

21 January 2018

1 reference

Genetic and Physical Mapping of theLpsLocus: Identification of the Toll-4 Receptor as a Candidate Gene in the Critical Region

21 January 2018

1 reference

Structural analysis of the nontoxic lipid A of Rhodobacter capsulatus 37b4.

21 January 2018

1 reference

E5531, a pure endotoxin antagonist of high potency

21 January 2018

1 reference

Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins

21 January 2018

1 reference

Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers

21 January 2018

1 reference

Inhibition of endotoxin response by synthetic TLR4 antagonists

21 January 2018

1 reference

21 January 2018

1 reference

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

Early goal-directed therapy in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

21 January 2018

1 reference

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

21 January 2018

1 reference

Hydrocortisone therapy for patients with septic shock

21 January 2018

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

Intensive versus conventional glucose control in critically ill patients

21 January 2018

1 reference

The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.

21 January 2018

1 reference

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

21 January 2018

1 reference

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

21 January 2018

1 reference

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

21 January 2018

1 reference

A controlled trial of HA-1A in a canine model of gram-negative septic shock.

21 January 2018

1 reference

The sirens' songs of confirmatory sepsis trials: selection bias and sampling error.

21 January 2018

1 reference

Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels

21 January 2018

1 reference

Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria

21 January 2018

1 reference

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

21 January 2018

1 reference

Bactericidal/permeability-increasing protein--lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia

21 January 2018

1 reference

Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion

21 January 2018

1 reference

Neutralization of endotoxin by a phospholipid emulsion in healthy volunteers.

21 January 2018

1 reference

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial

21 January 2018

1 reference

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.

21 January 2018

1 reference

Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors

21 January 2018

1 reference

Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review

21 January 2018

1 reference

Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

21 January 2018

1 reference

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist

21 January 2018

1 reference

Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.

21 January 2018

1 reference

Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations

21 January 2018

1 reference

Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia

21 January 2018

1 reference

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

21 January 2018

1 reference

Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia

21 January 2018

1 reference

APACHE II: a severity of disease classification system

21 January 2018

1 reference

TLR4: the receptor bridging Acanthamoeba challenge and intracellular inflammatory responses in human corneal cell lines

21 January 2018

1 reference

Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria

21 January 2018

1 reference

Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility

21 January 2018

1 reference

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.

21 January 2018

1 reference

TLR4 is essential in acute lung injury induced by unresuscitated hemorrhagic shock

21 January 2018

1 reference

Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury

21 January 2018

1 reference

Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen

21 January 2018

1 reference

House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells

21 January 2018

1 reference

Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice

21 January 2018

1 reference

Injury, sepsis, and the regulation of Toll-like receptor responses

21 January 2018

1 reference

TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.

21 January 2018

1 reference

TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

21 January 2018

1 reference

Invited review: deterioration of the immune system after trauma: signals and cellular mechanisms

21 January 2018

1 reference

Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures

21 January 2018

1 reference

Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling

21 January 2018

1 reference

CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer

21 January 2018

1 reference

Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction

21 January 2018

1 reference

Toll-dependent selection of microbial antigens for presentation by dendritic cells

21 January 2018

1 reference

CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.11.27

1 reference

24 August 2017

1 reference